Dana-Farber Cancer Institute | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana-Farber Cancer Institute

Dr Hantel on Environmental and Health Impacts of Decentralizing Cancer Care

August 15, 2024

Video

Andrew Hantel, MD, discusses the environmental and health impacts of decentralizing cancer care in response to high emissions generated by health care.

Dr Ravi on Neoadjuvant ARPIs Prior to Radical Prostatectomy in Prostate Cancer

August 14, 2024

Video

Praful K. Ravi, MB, BChir, MRCP, discusses the use of neoadjuvant androgen receptor pathway inhibitors prior to radical prostatectomy in high-risk, localized prostate cancer.

Dr Waks on Anthracycline- vs Taxane-Based Therapy in HER2+ Breast Cancer

August 13, 2024

Video

Adrienne G. Waks, MD, discusses how neoadjuvant and adjuvant anthracycline- and taxane-based regimens compare with one another in HER2+ breast cancer.

Dealing With Progression in HR+/HER2– mBC: Could a CDK4/6 Inhibitor Swap be the Solution?

August 11, 2024

Article

Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Dr Steiner on a Microdevice for Evaluating Responses to RCC Treatment

August 09, 2024

Video

Clara Steiner, MD, discusses a pilot study of an implantable microdevice for in vivo evaluation of drug responses in renal cell carcinoma.

Dr Machaalani on the Interaction Between c-Met and AXL in RCC

August 09, 2024

Video

Marc Machaalani, MD, discusses the rationale for examining AXL and its interaction with c-Met in renal cell carcinoma.

Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC

August 08, 2024

Podcast

Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.

Dr Saad on the Association Between IL-7 SNPs and Immune-Related AEs in RCC

August 08, 2024

Video

Eddy Saad, MD, MSc, discusses the association between an IL-7 SNP and immune-related AEs in patients with RCC who received immune checkpoint inhibitors.

Treatment After Progression on CDK4/6 Inhibitors Requires Careful Consideration in HR+/HER2– mBC

August 08, 2024

Article

Sarah Sammons, MD, describes how she treats patients with HR-positive, HER2-negative metastatic breast cancer who progressed on prior CDK4/6 inhibitors.

Novel Studies Seek to Optimize HER2+ Breast Cancer Management

August 07, 2024

Article

Sara M. Tolaney, MD, MPH, discusses the use of ADCs in HER2-positive breast cancer and ongoing research in this patient population.

Dr Tolaney on Data With Checkpoint Inhibitor Combinations in Metastatic TNBC

August 07, 2024

Video

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.

Dana-Farber's Edward Chouchani selected as a Howard Hughes Medical Institute Investigator

August 07, 2024

Article

Edward Chouchani, PhD, of Dana-Farber Cancer Institute, has been named a Howard Hughes Medical Institute Investigator.

Emerging HER2+ Breast Cancer Research Uses Innovative Combinations of Standard Agents

August 06, 2024

Article

Sara M. Tolaney, MD, MPH, discusses the HER2-positive breast cancer treatment paradigm and how standard agents may be optimized to improve outcomes.

Residual Cancer Burden May Prognosticate Outcomes With Neoadjuvant Therapy in Prostate Cancer

August 06, 2024

Article

Praful Ravi, MB, BChir, MRCP, discusses an analysis measuring residual cancer burden in localized prostate cancer after neoadjuvant therapy and surgery.

Dr Florez on Addressing Key Gaps in Lung Cancer Care

August 05, 2024

Video

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.

Dr Rotow on Challenges With Targeting CNS Metastases in Lung Cancer

August 01, 2024

Video

Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.

First-Line Avelumab Maintenance Extends OS in Advanced Urothelial Carcinoma With Low Tumor Burden

July 30, 2024

Article

First-line avelumab maintenance demonstrated efficacy and manageable toxicity in patients with low tumor burden advanced urothelial carcinoma.

Tolaney Details IHC Testing Considerations for HER2-Low TNBC and Data on ADCs

July 29, 2024

Article

Sara M. Tolaney, MD, MPH, shares biopsy considerations when determining HER2-low status for patients with TNBC and details data within the TNBC landscape.

Dr Ravi on the Potential Use of RCB to Inform Neoadjuvant Strategies in High-Risk Prostate Cancer

July 29, 2024

Video

Praful K. Ravi, MB, BChir, MRCP, discusses the use of residual cancer burden to guide intensified neoadjuvant treatment in high-risk prostate cancer.

Tarantino Talks Limitations in HER2-Low Breast Cancer Management, Key Advancements in HER2+/TNBC

July 28, 2024

Article

Paolo Tarantino, MD, discusses current treatment landscapes and looks to the future in HER2-low breast cancer, HER2-positive breast cancer, and TNBC.